



Immunization Schedules

CDC > Schedules Home > For Healthcare Providers > Child & Adolescent Immunization Schedule

Child and Adolescent Immunization Schedule by Age

Recommendations for Ages 18 Years or Younger, United States, 2024

Print

Back to Child and Adolescent Immunization Schedule home page

Vaccines and Other Immunizing Agents in the Child Immunization Schedule

Get email updates

How to use the schedule

To make vaccination recommendations, healthcare providers should:

1. Determine recommended vaccine by age (Table 1 – By Age)

2. Determine recommended interval for catch-up vaccination (Table 2 – Catch-up)

3. Assess need for additional recommended vaccines by medical condition or other indication (Table 3 – By Medical Indication)

4. Review vaccine types, frequencies, intervals, and considerations for special situations (Notes)

5. Review contraindications and precautions for vaccine types (Appendix)

6. Review new or updated ACIP guidance (Addendum)

Download the Schedule

[Print the schedule, color](#)

[Print the schedule, black & white](#)

[Download the mobile app](#)

Compliant version of the schedule

Legend

Range of recommended ages for all children

Range of recommended ages for catch-up vaccination

Range of recommended ages for certain high-risk groups

Recommended vaccination can begin in this age group

Recommended vaccination based on shared clinical decision-making

No recommendation/not applicable

Birth to 15 Months

These recommendations must be read with the notes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars. To determine minimum intervals between doses, see the catch-up schedule (Table 2).

agents	Birth	1 mo	2 mos	4 mos	6 mos	9 mos	12 mos	15 mos
<a href="#">Respiratory syncytial virus</a> ⓘ (RSV-mAb [Nirsevimab])	1 dose depending on maternal RSV vaccination status, See <a href="#">notes</a>					1 dose (8 through 19 months), See <a href="#">notes</a>		
<a href="#">Hepatitis B</a> ⓘ (HepB)	1 <sup>st</sup> dose	←2 <sup>nd</sup> dose→			←3 <sup>rd</sup> dose→			
<a href="#">Rotavirus (RV)</a> ⓘ RV1 (2-dose series); RV5 (3-dose series)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	See <a href="#">notes</a>			
<a href="#">Diphtheria, tetanus, &amp; acellular pertussis</a> ⓘ (DTaP: <7 yrs)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	3 <sup>rd</sup> dose		←4 <sup>th</sup> dose→	
<a href="#">Haemophilus influenzae type b</a> ⓘ (Hib)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	See <a href="#">notes</a>		←3 <sup>rd</sup> or 4 <sup>th</sup> dose, See <a href="#">notes</a> →	
<a href="#">Pneumococcal conjugate</a> ⓘ (PCV15, PCV20)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	3 <sup>rd</sup> dose		←4 <sup>th</sup> dose→	
<a href="#">Inactivated poliovirus</a> ⓘ (IPV: <18 yrs)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	←3 <sup>rd</sup> dose→			
<a href="#">COVID-19</a> ⓘ (1vCOV-mRNA, 1vCOV-aPS)						1 or more doses of updated (2023–2024 Formula) vaccine (See <a href="#">notes</a> )		
<a href="#">Influenza</a> (IIV4) ⓘ						Annual vaccination 1 or 2 doses		
or								
<a href="#">Influenza</a> (LAIV4) ⓘ								
<a href="#">Measles, mumps, rubella</a> ⓘ (MMR)						See <a href="#">notes</a>	←1 <sup>st</sup> dose→	
<a href="#">Varicella</a> ⓘ (VAR)							←1 <sup>st</sup> dose→	
<a href="#">Hepatitis A</a> ⓘ (HepA)						(See <a href="#">notes</a> )	←2-dose series, See <a href="#">notes</a> →	
<a href="#">Tetanus, diphtheria, &amp; acellular pertussis</a> ⓘ (Tdap: ≥7 yrs)								
<a href="#">Human papillomavirus</a> ⓘ (HPV)								
<a href="#">Meningococcal</a> ⓘ (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)			See <a href="#">notes</a>					
<a href="#">Meningococcal B</a> ⓘ (MenB-4C, MenB-FHbp)								
<a href="#">Respiratory syncytial virus vaccine</a> ⓘ (RSV [Abrysvo])								
<a href="#">Dengue</a> ⓘ (DEN4CYD: 9-16 yrs)								
<a href="#">Mpox</a> ⓘ								

18 Months to 18 Years

Vaccine and other immunizing agents	18 mos	19-23 mos	2-3 yrs	4-6 yrs	7-10 yrs	11-12 yrs	15 yrs	16 yrs	17-18 yrs
<a href="#">Respiratory syncytial virus</a> ⓘ (RSV-mAb [Nirsevimab])	1 dose (8 through 19 months), See <a href="#">notes</a>								
<a href="#">Hepatitis B</a> ⓘ (HepB)	←3 <sup>rd</sup> dose→								
<a href="#">Rotavirus</a> ⓘ (RV) RV1 (2-dose series); RV5 (3-dose series)									
<a href="#">Diphtheria, tetanus, &amp; acellular pertussis</a> ⓘ (DTaP: <7 yrs)	←4 <sup>th</sup> dose→			5 <sup>th</sup> dose					
<a href="#">Haemophilus influenzae type b</a> ⓘ (Hib)									
<a href="#">Pneumococcal conjugate</a> ⓘ (PCV15, PCV20)									
<a href="#">Inactivated poliovirus</a> ⓘ (IPV: <18 yrs)	←3 <sup>rd</sup> dose→			4 <sup>th</sup> dose					See <a href="#">notes</a>
<a href="#">COVID-19</a> ⓘ (1vCOV-mRNA, 1vCOV-aPS)	1 or more doses of updated (2023–2024 Formula) vaccine (See <a href="#">notes</a> )								
<a href="#">Influenza</a> (IIV4) ⓘ or <a href="#">Influenza</a> (LAIV4) ⓘ	Annual vaccination 1 or 2 doses					Annual vaccination 1 dose only			
		Annual vaccination 1 or 2 doses			Annual vaccination 1 dose only				
<a href="#">Measles, mumps, rubella</a> ⓘ (MMR)				2 <sup>nd</sup> dose					
<a href="#">Varicella</a> ⓘ (VAR)				2 <sup>nd</sup> dose					
<a href="#">Hepatitis A</a> ⓘ (HepA)	← 2-dose series, See <a href="#">notes</a> →								
<a href="#">Tetanus, diphtheria, &amp; acellular pertussis</a> ⓘ (Tdap: ≥7 yrs)						1 dose			
<a href="#">Human papillomavirus</a> ⓘ (HPV)							See <a href="#">notes</a>		
<a href="#">Meningococcal</a> ⓘ (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)	See <a href="#">notes</a>					1 <sup>st</sup> dose		2 <sup>nd</sup> dose	
<a href="#">Meningococcal B</a> ⓘ (MenB-4C, MenB-FHbp)						See <a href="#">notes</a>			
<a href="#">Respiratory syncytial virus vaccine</a> ⓘ (RSV [Abrysvo])						Seasonal administration during pregnancy, See <a href="#">notes</a>			
<a href="#">Dengue</a> ⓘ (DEN4CYD: 9-16 yrs)						Seropositive in endemic dengue areas (See <a href="#">notes</a> )			
<a href="#">Mpox</a> ⓘ									

To make vaccination recommendations, healthcare providers should:

1. Determine recommended vaccine by age (Table 1 – By Age)

2. Determine recommended interval for catch-up vaccination (Table 2 – Catch-up)

3. Assess need for additional recommended vaccines by medical condition or other indication (Table 3 – By Medical Indication)
4. Review vaccine types, frequencies, intervals, and considerations for special situations (Notes)

5. Review contraindications and precautions for vaccine types (Appendix)

6. Review new or updated ACIP guidance (Addendum)

Recommended by the Advisory Committee on Immunization Practices (ACIP) and approved by the Centers for Disease Control and Prevention (CDC), American Academy of Pediatrics (AAP), American Academy of Family Physicians (AAFP), American College of Obstetricians and Gynecologists (ACOG), American College of Nurse-Midwives (ACNM), American Academy of Physician Associates (AAPA), and National Association of Pediatric Nurse Practitioners (NAPNP).

The comprehensive summary of the ACIP recommended changes made to the child and adolescent immunization schedule can be found in the [January 11, 2024 MMWR](#).

Report

- Suspected cases of reportable vaccine-preventable diseases or outbreaks to your state or local health department
- Clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) at [www.vaers.hhs.gov](#) or (800-822-7967)

Questions or comments  
Contact [www.cdc.gov/cdc-info](#) or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays.

Helpful information

- [Complete Advisory Committee on Immunization Practices \(ACIP\) recommendations](#)
- [ACIP Shared Clinical Decision-Making Recommendations](#)
- [General Best Practice Guidelines for Immunization \(including contraindications and precautions\)](#)
- [Vaccine information statements](#)
- [Manual for the Surveillance of Vaccine-Preventable Diseases \(including case identification and outbreak response\)](#)

Top of Page